A Technical Strategy for BioCryst Pharmaceuticals Inc. (BCRX), PPL Corporation (PPL)

You should consider shares of BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) and PPL Corporation (NYSE:PPL) if you are looking for a great stocks to invest in. Starting with the BCRX shares, which traded at $2.84 at the close of the recent session, gaining 2.90%. On Tuesday, the company’s shares shed $0.08 from its value which represented in intraday trading. The stock is now -69.06% lower in year-to-date (YTD) trading. BCRX’s intraday high was $2.85 while its lowest price touched $2.655. The stock’s 52-week high price is $9.95, which means the current price is at -71.46%. In terms of trading activity, the daily trading volume rose to 3421267 against 200-day average trading volume of 1,879,055 shares.

What are analyst forecasts for BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)?

At a consensus rating of 4.50, BCRX is trending as a streaking Strong Buy, as it has been the case a month ago when 8 analysts called it a Moderate Buy. Two months ago, 8 analysts recommended, on average, that BCRX stock is a Moderate Buy. The Healthcare company’s shares’ overall bullish trend saw it close higher on Tuesday compared to its opening price of $2.73 on the day.

Forecasts for BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) give the stock a fair value for the growth of 52.67% from its last price. The 12-month price forecast for the stock by analysts puts the stock’s mean price target at $6.00, which means the price per share could rise by nearly $3.16. The price range target is between a low of $4.00 and a high of $13.00. The stock would need to gain by about $78.15 to hit the estimated high or 0.49% from its 12-month low.

The consensus among 9 analysts is that it is a good time for one to Overweight in the BioCryst Pharmaceuticals Inc. 6 analysts rate BCRX as a Buy, with 0 of 9 analysts rate it as a Sell. 0 have valued the stock as Overweight and 3 have recommended that investors Hold.

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) Upgrades and Downgrades

In terms of rating changes, BofA/Merrill on November 15, 2019, Upgrade BioCryst Pharmaceuticals Inc. (BCRX) at Buy. They believe the stock could reach $4 in the near term. Analysts at RBC Capital Mkts have assigned a Sector Perform rating for the stock in their research note on May 24, 2019 with an estimated price target of $4.50. Moreover, Piper Jaffray analysts issued a rating of Overweight for the stock on November 16, 2018, giving it a price target of $15 for the next 12 months. On August 08, 2018, the stock earned a Overweight rating due to an analyst call from JP Morgan, while analysts from BofA/Merrill on July 17, 2018 suggested that the stock is Neutral.

PPL Corporation (NYSE:PPL) adds $0.0 on Tuesday

The PPL stock has risen 20.68% year-to-date and is currently trading at $34.19, which is -0.61% below its 52-week high. The company shares lost 0.00% on the day and have risen nearly 25.19% off a low hit. At current levels, PPL Corporation has a valuation of about $7.75B. As of 12/03/19, this stock has risen 0.97% during the week and closed at $34.19 in the previous session. However, recent PPL Corporation stock performance shows that PPL shares are 1.79% up over the last month, and 15.16% up for the last three months.

Earnings per share (EPS) estimates for the current quarter are $0.49, with the trailing 12-month share earnings at $2.46. The ratio is expected to be up by 1.30% for the current year 2019 and 3.70% for next year. Over the next 5-year period, earnings per share will be 0.50%. But will the PPL stock surprise in the current quarter results, where the $0.61 actual EPS reported on 9/29/2019 surprised by -1.60% or was lower by -$0.01 from the estimated $0.62.

Sales Growth to climb 3.80% for the year

How well will PPL Corporation perform as a business over the current quarter, year and next 5-year period? Compared to the year-ago quarter, analysts forecast the company to bring in between $1.99B and $2.15B in current quarter sales. The consensus estimated for the current quarter is $2.05B from sales. Forecasts for this fiscal year are between $7.81B and $8.06B and the consensus estimate for sales is at $7.93B. PPL has its next quarter sales estimates at between $2.13B and $2.15B, with the quarter-over-quarter growth estimates at -2.30% and the annual growth forecast for the year at 3.80%.

Who owns shares in PPL Corporation (PPL)?

Let’s briefly focus on the share ownership of the PPL Corporation (NYSE:PPL) stock, where we find that 59.05% of shares are held by institutions. Vanguard Group, Inc. (The) tops the list of institutional owners as it is holding 61.52 million shares or 8.51% of shares outstanding. Blackrock Inc. and State Street Corporation held 59.39 million and 38.1 million representing 8.21% and 5.27% respectively at the close of the last trading session. As of Sep 29, 2019, FMR, LLC accounted for 28.79 million shares at over 906.73 million. This represented 3.98% of shares outstanding. Invesco Ltd. held 27.85 million shares at over 876.95 million representing 3.85% of shares outstanding.

PPL Insider Activity

Insider activity can also give a signal in terms of price direction. Looking at PPL Corporation (PPL), a total of 641786 shares have been sold by insiders over the last 6 months while 638004 shares were added in the same time span. On 11/01/2019, Chairman & Chief Executive Officer by the name Spence William Harold sold 253009.0 shares worth $8.5 million at the price of $33.51 per share. Filings also show that Spence William Harold sold a total of 215020.0 shares on 10/22/2019 valued at $7.1 million. Since the last insider activity, the company’s share price has climbed 4.43%.